Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

NCT02955550 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.

NCT NCT02955550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma
Lead sponsor
Celularity Incorporated
Phase
Phase 1
Overall status
Completed
Start date
January 5, 2017
Completion date
June 4, 2019
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma